COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer (EMERGING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01407822
Recruitment Status : Active, not recruiting
First Posted : August 2, 2011
Last Update Posted : September 11, 2018
Guangdong Provincial People's Hospital
Tianjin Medical University Cancer Institute and Hospital
Jilin Provincial Tumor Hospital
Jiangsu Cancer Institute & Hospital
Zhejiang Cancer Hospital
Beijing Cancer Hospital
Sun Yat-sen University
West China Hospital
The First Affiliated Hospital of Dalian Medical University
Peking University People's Hospital
Health Science Center of Xi’an Jiaotong University
Shanghai Zhongshan Hospital
Guangzhou General Hospital of Guangzhou Military Command
The First Affiliated Hospital of Guangzhou Medical University
Fujian Medical University Union Hospital
Linyi Tumour Hospital
Northern Jiangsu Province People's Hospital
Information provided by (Responsible Party):
Yi-Long Wu, Guangdong Association of Clinical Trials

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : April 24, 2018
Estimated Study Completion Date : December 2022
Publications automatically indexed to this study by Identifier (NCT Number):